XLRN News and Press, Acceleron Pharma Inc. From 02/10/20

Biotech has been one of the big winners of this aging bull market. Over the past 10 years, biotech stocks, on balance, have absolutely clobbered the broader U.S. stock markets. The reason is simple: innovation. Through the advent of game-changing molecular, cellular, and genetic technologies, bi...

Shares of the mid-cap drugmaker Acceleron Pharma (NASDAQ: XLRN) gained a staggering 71.2% during the month of January, according to data from  S&P Global Market Intelligence . The biotech's stock skyrocketed late last month in response to positive midstage trial  results ...

Last week,  Acceleron Pharma (NASDAQ: XLRN) announced positive clinical trial results for its drug to treat a type of high blood pressure, causing its stock to skyrocket over 75%. After a jump that big, investors need to determine if the stock still has room to grow. Image source: Get...

Citing "substantial upside potential" in pulmonary arterial hypertension (PAH), Morgan Stanley has upgraded Acceleron Pharma ( XLRN +2.4% ) to Overweight with a boost in its fair value target to $122 (33% upside) from $52. More news on: Acceleron Pharma Inc., Healthcare stocks news, Stoc...

Acceleron Pharma ( XLRN ) announced that it had achieved the primary endpoint in the phase 2 PULSAR study, treating patients with pulmonary arterial hypertension ((PAH)). This positive data is only the beginning for this program, because there is another phase 2 study known as SPECTRA, whi...

Wall Street calls Geron (NASDAQ: GERN) a strong buy, so there is clearly a good deal of excitement about the stock, but also a good deal of risk. The question of whether to buy shares of the biotech company today isn't an easy one to answer for one good reason: Geron, at least as of now...

Gainers: Armata Pharmaceuticals (NYSEMKT: ARMP )  +104% . More news on: Armata Pharmaceuticals, Inc., NantHealth, Inc., Delphi Technologies PLC, Stocks on the move, , Read more ...

Shares of Acceleron Pharma (NASDAQ: XLRN) are up 41% at 11:19 a.m. EST following a report  after the closing bell yesterday that the company's heart drug sotatercept was successful in a phase 2 clinical trial in patients with pulmonary arterial hypertension (PAH), a disease characteriz...

Ocean Bio-Chem (NASDAQ: OBCI ) +80%  as its subsidiary Star brite announces registered EPA product kills the Coronavirus . More news on: Ocean Bio-Chem, Inc., Happiness Biotech Group Limited, Delphi Technologies PLC, Stocks on the move, , Read more ...

Shares of Acceleron Pharma (NASDAQ: XLRN) shot up significantly in after-hours trading on Monday when the company announced positive results for its drug to treat pulmonary arterial hypertension (PAH). A phase 2 clinical trial of Acceleron's drug candidate, sotatercept, met both the primary ...